This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Karyotakis, N. C. Articles by Anaissie, E. J. Search for Related Content PubMed PubMed Citation Articles by Karyotakis, N. C. Articles by Anaissie, E. J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, Feb 1995, 571-573, Vol 39, No. 2
Copyright © 1995 by the American Society for Microbiology. All rights reserved.

Activities of D0870, a novel triazole, against Candida lusitaniae and Trichosporon beigelii in experimental murine infections

NC Karyotakis, MC Dignani, R Hachem and EJ Anaissie
Department of Medical Specialties, University of Texas M. D. Anderson Cancer Center, Houston 77030, USA.

Candida lusitaniae and Trichosporon beigelii may cause life-threatening infections in the immunocompromised host and may be resistant to amphotericin B. We assessed the activities of a new triazole, D0870, against one T. beigelii and four C. lusitaniae strains, in comparison with those of fluconazole and amphotericin B. Immunosuppressed CF1 mice, intravenously infected with each fungal strain, received 3 days of therapy with oral D0870 (5 or 25 mg/kg of body weight daily), fluconazole (5 to 50 mg/kg daily), or parenteral amphotericin B (1 or 2 mg/kg daily). Survival was significantly prolonged and kidney fungus titers were reduced in mice treated with D0870 compared with untreated mice (P < or = 0.05). Treatment with D0870 was significantly more effective than that with amphotericin B or fluconazole in animals infected with two of the C. lusitaniae strains and equally effective for the remaining two C. lusitaniae strains and the T. beigelii strain. Fluconazole and amphotericin B failed to improve the survival of mice infected with one and two C. lusitaniae strains, respectively. D0870 was active against all the organisms tested, including those resistant to fluconazole and amphotericin B.

This article has been cited by other articles:

• De Wit, S., O'Doherty, E., Edwards, J., Yates, R., Smith, R. P., Clumeck, A. N. (1998). Pharmacokinetics of Two Multiple-Dosing Regimens of D0870 in Human Immunodeficiency Virus-Positive Patients: a Phase I Study. Antimicrob. Agents Chemother. 42: 903-906 [Abstract] [Full Text]